Newsroom | 53807 results

Sorted by: Latest

Research
-

Home Gardeners Highly Concerned about Lawns and Gardens during Droughts and Watering Bans

MINNEAPOLIS--(BUSINESS WIRE)--Home gardener concerns about droughts and watering bans remain high as heat domes happen throughout the nation this summer. Despite these concerns, many homeowners say they are largely unaware of water-saving products for their lawns and gardens, according to a new study from Axiom. “Concerns about keeping lawns and garden plants alive are high,” says Mike Reiber, CEO of Axiom, a Minneapolis-based market research firm that measures consumer attitudes on home and ga...
-

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected...
-

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B re...
-

Photonic Inc. Appoints Top Tech Leaders to Accelerate Quantum Innovation and Growth

VANCOUVER, British Columbia--(BUSINESS WIRE)--Photonic Inc.'s new executive appointments expedite growth as it accelerates the timeline to commercially useful quantum applications....
-

80% of Americans Say Quality Declines When Speed Takes Priority, Yooz Survey Shows

DALLAS--(BUSINESS WIRE)--A new survey by Yooz, a Cloud-based purchase-to-pay (P2P) automation provider, reveals that Americans are increasingly dissatisfied with the decline in quality that often accompanies the push for speed in business operations. According to the Yooz 2025 Business Speed Trap Report, 80% of Americans believe that when businesses prioritize speed, the quality of products and services suffers. At the same time, the survey highlights a troubling trend in the workforce, with 55...
-

Axcelead and A2 Healthcare Announce Strategic Partnership to Accelerate Drug R&D

TOKYO--(BUSINESS WIRE)--Axcelead, Inc. (Axcelead) and A2 Healthcare Corporation (A2 Healthcare) announced that they will enter a strategic partnership to promote pharmaceutical research and development in Japan. Axcelead operates a global business built on two core pillars: drug discovery services and mRNA CDMO services. Its drug discovery capabilities are provided through Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa) and Axcelead Tokyo West Partners, Inc. (Head...
-

MicroPure Genomics Awarded Competitive $1.25M SBIR Phase II Grant from the National Science Foundation

SAN DIEGO--(BUSINESS WIRE)--MicroPure Genomics Inc., a revolutionary sample prep technology company, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $1,250,000 to conduct research and development (R&D) work on redefining front-end sample preparation for genomic analysis in research and healthcare. "This NSF SBIR phase II award is a testament to the groundbreaking work our team is doing to redefine genomic sample preparation," said Rya...
-

Outcome Capital Announces Partnership of ZIEN Medical and Averra Holdings

BOSTON--(BUSINESS WIRE)--Highly specialized life sciences and healthcare advisory and investment banking firm supports medical device organization ZIEN execute partnership....
-

āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today announced that the first participant has been dosed in its Phase 1b clinical trial of andecaliximab in patients with spinal cord injury (SCI). The study, called ANDECA-HO, is evaluating patients who are at risk of developing heterotopic ossification (HO), a condition that causes abnormal bone form...
-

MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board...